Does Altr drop 6 pts Monday?!?!?
Analyst Ratings for ImmunoCellular Therapeutics (IMUC)
IMUC Rating Summary:
Buys – 5
Neutrals – 1
Sells – 0
IMUC Price Target Summary
Highest: $4.00 (Maxim Group)
Lowest: $3.00 (Roth Capital)
* Over Last 12-Mos
shorts may push WLL over 35
3 days ago Maxim also put a $3 target on IMUC.
I agree. I also found another recent $3 target on IMUC from Maxim Group. With these targets I would expect IMUC to hit $1.75 to $2.25 by this summer.
Maxim Group Reiterates a Buy Rating on ImmunoCellular Therapeutics (March 10th, 2015)
By Corrie Williams
In a report released today, Jason Kolbert from Maxim Group reiterated a Buy rating on ImmunoCellular Therapeutics (NYSE MKT: IMUC), with a price target of $3. The company’s shares closed yesterday at $0.55, close to its 52-week low of $0.53.
March 13th, 2015
ImmunoCellular Therapeutics Ltd (IMUC) Bullish Stance Reiterated at Roth Capital Following FY14 Results
Roth Capital’s healthcare analyst Joseph Pantginis weighed in today with a few insights on ImmunoCellular Therapeutics Ltd (NYSE MKT:IMUC), after the company reported full-year 2014 results, posting EPS of ($0.16) compared to Pantginis’ estimate of ($0.17) and consensus of ($0.15).
The analyst reiterated a Buy rating on the stock with a $3 price target, which represents a potential upside of 436% from where the stock is currently trading.
Pantginis noted, “We believe this year represents a turning point for IMUC with the expected Phase III study start with ICT-107 in newly diagnosed glioblastoma patients. IMUC also expects to have data from the Phase I study of ICT-121 in recurrent glioblastoma in 2016 as well as advance its in-licensed Stem-to-T-cell program to the clinic. We believe that as the company starts achieving these milestones, there will be renewed interest and focus in the ICT-140 asset for ovarian cancer which the company had put on hold until it finds either sufficient funds or a suitable partner to advance it into Phase II. We believe that visibility and renewed interest in the company should rise with initiation of the ICT-107 Phase III.”
Maybe not....Looks like MRV is using its cash to keep the stock up. About 3.5M left to spend. May hit that today if the selling continues.
Share price is close to CASH. Time for MRV to trim a bit and get the margins up.
Lots of cash flow.